FDA approves Neurotech therapy for rare eye disease
The FDA on Thursday approved Neurotech Pharmaceuticals’ cell therapy for an eye disease known as macular telangiectasia type 2, which causes central vision to become distorted and get worse over time ...
View ArticleStart of 2025 comes with generic drug price decreases, several major...
More generic drug prices decreased than increased in January, a new report from 46Brooklyn found. The report said for every generic drug price increase in January, 1.3 generic drugs saw their ...
View ArticleFDA and NIH nominees sail through Senate hearings; Tariffs’ early impact on...
Welcome back to Endpoints Weekly! This week was another busy one in DC, with two Senate hearings for Trump’s picks to lead the NIH and FDA, more actions from the Department of Government Efficiency,...
View ArticleSun Pharma to acquire Checkpoint Therapeutics and its anti-PD-L1 antibody
After months of searching for a partner for its recently approved cancer drug, Checkpoint Therapeutics has instead secured a buyer. India's Sun Pharma is acquiring the immuno-oncology biotech for $4.10...
View ArticleNovo Nordisk’s CagriSema shows 15.7% weight loss in second pivotal trial
Novo Nordisk’s CagriSema demonstrated weight loss of 15.7% in patients with both obesity and type 2 diabetes who took the drug for more than a year, the company said Monday. ...
View ArticleArrowhead reveals small batch of open-label data for 'non-core' kidney drug
Arrowhead Pharmaceuticals on Monday shared new open-label data in about a dozen patients for a program designed to improve certain kidney disease outcomes by targeting complement pathways. The program,...
View ArticleTrevi Therapeutics stock soars on Phase 2a chronic cough data
Trevi Therapeutics’ chronic cough drug reduced patients’ 24-hour cough frequency by 57% compared to placebo in a Phase 2a trial, exceeding investors’ expectations. The company’s stock {$TRVI} soared...
View ArticleJ&J, Protagonist outline first IBD win for potential immunological blockbuster
Johnson & Johnson and Protagonist Therapeutics have bet their oral IL-23 drug will be an immunology blockbuster, and they are now one step closer to that goal. The companies said Monday that the...
View ArticleMired in low expectations, Novo braces for upcoming CagriSema head-to-head trial
Novo Nordisk’s late-stage weight loss data showed CagriSema performed below analysts’ expectations. It's the second late-stage clinical letdown for the candidate, and the findings mean it is more vital...
View ArticleFDA blocks drug and device reviewers from taking HHS' buyout offer
The FDA told staff on Monday that reviewers of medical products and inspectors of manufacturing facilities cannot take the buyout offer circulated on Friday from HHS that would've provided as much as...
View Article#AAD25 roundup: Data from Amgen, Bristol Myers, J&J, Alumis and more
At this year’s American Academy of Dermatology annual meeting, companies like Amgen, Bristol Myers Squibb and Alumis took the stage to report the latest on their dermatology candidates. Here are the...
View ArticleBeam shares promising first clinical data on gene editing treatment
Beam Therapeutics said its experimental gene editing treatment helped lower levels of mutant proteins and increase levels of corrected proteins in nine people with a lung disease called alpha-1...
View ArticleEmergent sells once-troubled Baltimore site to Syngene
Emergent BioSolutions is selling a manufacturing site in Baltimore — which has a history of contaminated Covid-19 vaccines — for $36.5 million to India-headquartered CDMO Syngene. This purchase marks...
View ArticleFederal judge denies preliminary injunction in tirzepatide compounding case
Compounding pharmacies faced a major setback in their case over the FDA’s decision to remove the obesity drug tirzepatide from its official shortage list. The US District Court for the Northern...
View ArticleBioNTech's shares dip after posting lukewarm revenue guidance
BioNTech has forecast lackluster sales for 2025 despite ending last year on a relatively strong note, causing the drugmaker’s shares to slide about 2% on Monday. The Covid-19 vaccine maker said it...
View ArticleNew Flagship startup aims to trailblaze ‘AI science factories’
A new Flagship Pioneering startup has emerged with $200 million and a team of experts in both science and AI to pursue what it calls “scientific superintelligence.” Lila Sciences, announced by ...
View ArticleVirtual physical therapy startup Hinge Health files to go public
Virtual physical therapy startup Hinge Health on Monday filed to go public, snapping a dry spell of digital health IPOs. Hinge treats musculoskeletal injuries and chronic pain remotely using software....
View ArticleBristol Myers buys out cell therapy partner 2seventy bio
Bristol Myers Squibb will acquire its CAR-T cell therapy collaborator 2seventy bio for $286 million in cash, the companies said late Monday evening. Bristol Myers and 2seventy have been longtime...
View ArticleArvinas and Pfizer’s PROTAC vepdegestrant works in subset of breast cancer...
Arvinas and Pfizer’s targeted protein degrader has not managed to distinguish itself from other, similar breast cancer drugs, according to pivotal data released Tuesday. Results of the Phase 3...
View ArticleDefine Ventures hires former Aetion CEO Carolyn Magill
Former Aetion CEO Carolyn Magill has joined digital health venture firm Define Ventures as a venture partner. It’s the third big hire for Define over the past year, after also bringing on industry...
View Article